ALT Share Price Performance
US$0
-3.67 (-100.00%)
Price US$0
Fair ValueUS$17.22
Share Pricen/a
Narrative Update • Jul 29
Altimmune, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 44 Fair Values set on narratives written by author
ALT Community Narratives
AN
Fair Value
·Fair Value US$17.22 82.4% undervalued intrinsic discount
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$28 89.2% undervalued intrinsic discount
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
Altimmune is pushing a new drug that targets both weight and liver disease, and a key study update could move it closer to its first approval. The big question is whether it can stand out in a crowded field and avoid delays, financing strain, or disappointing results in its other liver and alcohol-related programs.Read more
AN
US$17.22
82.4% undervalued intrinsic discount
Fair Value
Profit Margin
17.18%
Future PE
1.67kx
Price in 2029
US$11.82
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
Catalysts About Altimmune Altimmune is a clinical stage biopharmaceutical company developing pemvidutide, a dual GLP-1 and glucagon agonist targeting MASH, alcohol use disorder and alcohol-associated liver disease. What are the underlying business or industry changes driving this perspective?Read more
AN
US$28
89.2% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
122.49x
Price in 2028
US$19.16
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ALT: MASH And Alcohol Use Disorder Data Will Drive Future Upside
Fair Value: US$17.22 82.4% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
Fair Value: US$28 89.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Altimmune, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 12, 2026
- -0.47
- -183,477.78%
- -253,002.78%
- 12.2%
About ALT
- Founded
- 1997
- Employees
- 57
- CEO
- WebsiteView website
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
